Five Prime Therapeutics, Inc. FPRX was a big mover last session, as the company saw its shares rise more than 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company as the stock is now down 30.1% in the past one-month time frame.
The company has seen three positive estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Five Prime Therapeutics. So, make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Five Prime Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Five Prime Therapeutics, Inc. Price
Five Prime Therapeutics, Inc. price | Five Prime Therapeutics, Inc. Quote
A better-ranked stock in the Medical - Biomedical and Genetics industry is Acorda Therapeutics, Inc. ACOR , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Is FPRX going up? Or down? Predict to see what others think: Up or Down
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98% , +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Five Prime Therapeutics, Inc. (FPRX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research